3 months to June 30, 6 months to June 30, 2013 2012 2013 2012 $M $M $M $M Net cash provided by operating activities 258.6 465.8 419.0 722.8 Up-front payments in respect of in-licensed and acquired products - - - 23.0 Capital expenditure (17.7) (32.7) (65.0) (64.4) Non GAAP free cash flow 240.9 433.1 354.0 681.4
Non GAAP net cash comprises:
June 30, December 31, 2013 2012 $M $M Cash and cash equivalents 1,301.9 1,482.2 Convertible bonds (1,100.0) (1,100.0) Other debt (8.9) (9.3) Non GAAP net cash 193.0 372.9
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, Internal Medicine and Regenerative Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.
FORWARD - LOOKING STATEMENTS - "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included in this announcement that are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that:
|SOURCE Shire plc|
Copyright©2012 PR Newswire.
All rights reserved